XML 49 R40.htm IDEA: XBRL DOCUMENT
v3.26.1

Significant Collaborative Research and License Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Aug. 31, 2024 | Dec. 31, 2021 | Sep. 30, 2021 | Oct. 31, 2017 | Jun. 30, 2026 | Dec. 31, 2025 | Jun. 30, 2025 | Mar. 31, 2025 | Sep. 30, 2024 | Jun. 30, 2022 | Jun. 30, 2026 | Jun. 30, 2025 | Dec. 31, 2017 | Dec. 31, 2016 | Mar. 31, 2026 | Dec. 31, 2024 | Apr. 30, 2024
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 68,036 |  | $ 62,227 |  |  |  | $ 126,881 | $ 123,863 |  |  |  |  |
Net sales |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |
Other Receivables, net |  |  |  |  | 2,703 | $ 6,404 |  |  |  |  | 2,703 |  |  |  |  |  | $ 3,500
Allergan License Agreement [Member] | Vitae Pharmaceuticals Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |  |
Potential milestone payments to be made |  |  |  | $ 99,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payable |  |  |  | $ 70,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Expenses Paid |  |  |  |  |  | 12,000 |  |  |  |  |  |  |  |  |  | $ 18,000 |
Development and regulaotry milestones Expenses |  |  |  |  | 38,000 |  |  |  |  |  | 38,000 |  |  |  |  |  |
License expiration year |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |
Ucb License Agreement [Member] | U C B Biopharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | $ 10,000 | $ 15,000 |  | 41,000 |  |  | $ 5,000 |  |  |
Potential milestone payments to be made |  |  |  |  |  |  |  |  |  |  |  |  |  | 119,500 |  |  |
Aggregate potential milestone payable |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 |  |  |
Milestone Expenses Paid |  |  |  |  | 150,000 |  |  |  |  |  | 150,000 |  |  |  |  |  |
License expiration year |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |
Milestone payment payable |  |  |  |  |  | 10,000 |  |  |  | $ 5,800 |  |  |  |  |  |  |
Collaboration And License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received | $ 12,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Receivables, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |
Common stock shares purchased |  | 1,421,523 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase price per share |  | $ 24.62 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of common stock |  | $ 35,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration receivable |  |  |  |  | 26,400 | 28,100 |  |  |  |  | 26,400 |  |  |  |  |  |
Collaboration revenue |  |  |  |  | 18,100 |  | $ 9,400 |  |  |  | 34,000 | $ 9,100 |  |  |  |  |
Collaboration expense due to counterparty |  |  |  |  | $ 4,000 | $ 4,400 |  |  |  |  | $ 4,000 |  |  |  |  |  |
Collaboration And License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments to be made |  | 220,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commercialization milestones and tiered royalties |  | 230,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement [Member] | Non-Refundable Cash Payments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront milestone payable |  | $ 117,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Global and U.S. [Member] | Collaboration And License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development costs associated with clinical trials |  |  | 45.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Global and U.S. [Member] | Collaboration And License Agreement [Member] | Incyte Corporation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development costs associated with clinical trials |  |  | 55.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ex-U.S. Countries [Member] | Collaboration And License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development costs associated with clinical trials |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Aggregate potential milestone payable. + References No definition available. + Details
Name: | sndx_AggregatePotentialMilestonePayable
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration expense due to counterparty. + References No definition available. + Details
Name: | sndx_CollaborationExpenseDueToCounterparty
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration receivable + References No definition available. + Details
Name: | sndx_CollaborationReceivable
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration Revenue + References No definition available. + Details
Name: | sndx_CollaborationRevenue
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commercialization milestones and tiered royalties. + References No definition available. + Details
Name: | sndx_CommercializationMilestonesAndTieredRoyalties
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development And Regulatory Milestones Expenses + References No definition available. + Details
Name: | sndx_DevelopmentAndRegulatoryMilestonesExpenses
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development costs associated with clinical trials. + References No definition available. + Details
Name: | sndx_DevelopmentCostsAssociatedWithClinicalTrials
Namespace Prefix: | sndx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreements expiration period. + References No definition available. + Details
Name: | sndx_LicenseAgreementsExpirationPeriod
Namespace Prefix: | sndx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Expenses Paid + References No definition available. + Details
Name: | sndx_MilestoneExpensesPaid
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment due. + References No definition available. + Details
Name: | sndx_MilestonePaymentDue
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Net Sales + References No definition available. + Details
Name: | sndx_NetSales
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential milestone payments upon achievement of milestone. + References No definition available. + Details
Name: | sndx_PotentialMilestonePaymentsUponAchievementOfMilestone
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payments. + References No definition available. + Details
Name: | sndx_UpfrontPayments
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount due from parties in nontrade transactions, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_OtherReceivables
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1 Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1 Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sndx_AllerganLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sndx_VitaePharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sndx_UcbLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sndx_UCBBiopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=sndx_NonRefundableCashPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=sndx_GlobalAndUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sndx_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |